Heat Biologics Inc (HTBX)

1.41
0.10 6.62
NASDAQ : Health Care
Prev Close 1.51
Open 1.56
Day Low/High 1.39 / 1.56
52 Wk Low/High 0.40 / 5.89
Volume 856.98K
Avg Volume 1.91M
Exchange NASDAQ
Shares Outstanding 19.49M
Market Cap 29.63M
EPS -2.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

7 Stocks Under $10 to Trade for Big Profits

7 Stocks Under $10 to Trade for Big Profits

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

8 Breakout Stocks Under $10 to Trade for Big Profits

8 Breakout Stocks Under $10 to Trade for Big Profits

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Heat Biologics And OncoSec Present Data At The American Conference For Cancer Research (AACR) Annual Meeting

Heat Biologics And OncoSec Present Data At The American Conference For Cancer Research (AACR) Annual Meeting

Preclinical findings demonstrate that intratumoral electroporation activate tumor neoantigen-specific immune responses

OncoSec And Heat Biologics Present Data At The American Conference For Cancer Research (AACR) Annual Meeting

OncoSec And Heat Biologics Present Data At The American Conference For Cancer Research (AACR) Annual Meeting

Preclinical findings demonstrate that intratumoral electroporation activates tumor neoantigen-specific immune responses

Heat Biologics Announces Cost-Saving Measures And Focused Corporate Strategy To Achieve Important Clinical Milestones

Heat Biologics Announces Cost-Saving Measures And Focused Corporate Strategy To Achieve Important Clinical Milestones

Cost-saving measures enable Heat to achieve Phase 2 HS-410 bladder cancer data readout in 4Q:16 with its current cash on-hand

Heat Biologics Reports Fiscal Year 2015 Financial Results

Heat Biologics Reports Fiscal Year 2015 Financial Results

Phase 2 Topline Data Expected in the Fourth Quarter of 2016 Evaluating HS-410 in Combination With BCG

FDA Lifts Heat Biologics Partial Clinical Hold

FDA Lifts Heat Biologics Partial Clinical Hold

Heat to Resume Patient Enrollment in Its Phase 2 HS-410 Monotherapy Arm